C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.510
+0.110 (3.24%)
At close: Sep 11, 2026, 4:00 PM EDT
3.500
-0.010 (-0.28%)
After-hours: Sep 11, 2026, 7:30 PM EDT
C4 Therapeutics Employees
C4 Therapeutics had 104 employees as of December 31, 2025. The number of employees decreased by 6 or -5.45% compared to the previous year.
Employees
104
Change (1Y)
-6
Growth (1Y)
-5.45%
Revenue / Employee
$336,913
Profits / Employee
-$975,154
Market Cap
431.82M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 104 | -6 | -5.45% |
| Dec 31, 2024 | 110 | -35 | -24.14% |
| Dec 31, 2023 | 145 | -1 | -0.68% |
| Dec 31, 2022 | 146 | 25 | 20.66% |
| Dec 31, 2021 | 121 | 22 | 22.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Arcturus Therapeutics Holdings | 111 |
| Editas Medicine | 87 |
| Larimar Therapeutics | 71 |
| Rezolute | 68 |
| Atea Pharmaceuticals | 55 |
| Inhibikase Therapeutics | 35 |
| Fennec Pharmaceuticals | 35 |
| Benitec Biopharma | 19 |
CCCC News
- 3 days ago - C4 Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 10 days ago - C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics reports Q2 EPS (18c), consensus (23c) - TheFly
- 4 weeks ago - C4 Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - C4 Therapeutics Quarterly report: Q2 2026 - Filings
- 4 weeks ago - C4 Therapeutics Slides: Corporate presentation - Filings
- 2 months ago - C4 Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - C4 Therapeutics Transcript: KOL event - Transcripts